Highest-materiality recent filing
Cypherpunk Technologies 2026 annual meeting results: directors elected, say-on-pay approved
Will McEvoy and Nissim Mashiach elected as Class III directors with 24.9M and 22.2M votes for, respectively.
Cypherpunk regains compliance with Nasdaq minimum bid price rule
Received Nasdaq notice on May 21, 2026 confirming compliance with Listing Rule 5550(a)(2).
Cypherpunk Q1 net loss $77.2M as $77.6M unrealized ZEC loss hits earnings
Net loss $77.2M vs $15.4M YoY; $77.6M unrealized loss on ZEC marked to market.
Four directors to retire from Cypherpunk board at 2026 annual meeting
Drs. Mirabelli, Loscalzo, Schilsky, and Cavanaugh resign effective immediately before the 2026 Annual Meeting.
Cypherpunk reports FY2025 net income of $4.8M; ZEC treasury at $147.4M
Net income of $4.8M vs net loss of $67.8M in 2024; driven by $50.4M unrealized gain on ZEC holdings.
Nasdaq notified Cypherpunk that its common stock closing bid price was below $1.00 for 30 consecutive business days.
Cypherpunk buys additional 56,418 ZEC for ~$29M, total holdings reach 290,063 ZEC (1.76% of supply)
Purchased 56,418.09 ZEC at $514.02/ZEC for ~$29 million.
Cypherpunk grants 5.45M RSUs to consultant CoinXit; cancels prior award
Granted 5,448,157 RSUs under 2025 Equity Incentive Plan; cancels prior 2,411,700 RSUs under 2022 Plan.
Stockholders approved the 2025 Equity Incentive Plan covering up to 31,454,785 shares of common stock.
Cypherpunk Technologies (CYPH) signed a waiver agreement with Winklevoss Capital on November 19, 2025, modifying the October 8, 2025 common warrant.
Cypherpunk buys additional $18M of Zcash, now holds 1.43% of network
Purchased 29,869.29 ZEC for $18M at average price $602.63/ZEC on November 18, 2025.
Leap Therapeutics rebrands as Cypherpunk, buys $50M ZEC, appoints new leaders
Company renamed Cypherpunk Technologies; stock ticker changes from LPTX to CYPH on Nov 13, 2025.
Company entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to sell up to $200M of common stock.
Leap's sirexatamab shows statistically significant PFS/OS benefit in DKK1-high CRC at ESMO 2025
In DKK1-high (upper median, n=88): mPFS 9.03 vs 7.06 mo (HR 0.61, p=0.0255); mOS not reached vs 14.39 mo (HR 0.42, p=0.0118).
Gross proceeds of ~$58.88M from sale of 15.2M shares, 80.8M pre-funded warrants, and 72.0M common warrants.
$58,888,888 in cash commitments for PIPE offering at $0.61439 per unit, led by Winklevoss Capital.
Leap Therapeutics gets Nasdaq bid price extension to March 9, 2026
Nasdaq granted additional 180-day compliance period until March 9, 2026, for minimum $1.00 bid price.
Leap Therapeutics Q2 net loss $16.6M, cuts workforce 75%, explores strategic alternatives
Net loss of $16.6M for Q2 2025 vs $20.4M in Q2 2024; cash and equivalents $18.1M at June 30, 2025.
Leap reports sirexatamab PFS benefit in CRC subgroups; workforce cut 75%, strategic review
DeFianCe study: in high-DKK1 pts (upper quartile), median PFS 9.36 vs 5.88 mo (HR 0.47, p=0.024); ORR 44% vs 15.8% (p=0.015).
Leap Therapeutics Q1 net loss $15.4M; workforce cut ~50%; sirexatamab shows positive Phase 2 data
Net loss of $15.4M in Q1 2025 vs $13.8M in Q1 2024; R&D expense rose to $12.9M.
Leap reports positive sirexatamab CRC data: 32% higher ORR, 3.5mo PFS in high DKK1 patients
High DKK1 patients: sirexatamab arm ORR 48% vs 15.8% control; median PFS 9.36 vs 5.88 mo (HR 0.46); OS HR 0.09.
Leap Therapeutics receives Nasdaq deficiency notice for low bid price; 180 days to cure
Closing bid price below $1.00 for 30 consecutive business days as of March 12, 2025.
Part B DeFianCe (n=188): sirexatamab arm ORR 35% vs control 23%; DCR 86% vs 84%.
Leap Therapeutics Q3 net loss $18.2M; DKN-01 CRC enrollment complete, data mid-2025
Net loss of $18.2M for Q3 2024, up from $13.7M YoY, driven by higher R&D expenses.
Leap Therapeutics completes enrollment of 188 patients in Phase 2 DeFianCe study of DKN-01 for CRC
Enrolled 188 patients in randomized controlled Part B of DeFianCe study (NCT05480306).
Leap Therapeutics Q2 net loss $20.4M; DKN-01 ORR 33% in CRC; $40M PIPE completed
Net loss of $20.4M in Q2 2024 vs $13.4M in Q2 2023; R&D expenses rose to $17.9M on trial costs.
James Cavanaugh, Douglas Onsi, Christian Richard, and Richard Schilsky elected Class I directors with over 16.7 million votes each.
Leap Therapeutics reports Q1 2024 net loss of $13.8M; completes $40M private placement
Net loss of $13.8M for Q1 2024 vs $41.9M Q1 2023; decrease due to $29.6M IPR&D expense from Flame merger in prior year.
Leap Therapeutics raises $40M in private placement to fund DKN-01 clinical trials
Gross proceeds ~$40M from sale of 12.66M shares at $2.82 and pre-funded warrants for 1.52M shares at $2.819.
Leap Therapeutics reports FY2023 net loss $81.4M; cash $70.6M; DKN-01 data positive
Net loss $81.4M in FY2023 vs $54.6M in FY2022; R&D expenses $73.2M.
Company filed Form 8-K on Jan 23, 2024, stating it posted an updated corporate presentation on its website.
Across 27 evaluable microsatellite stable CRC patients: ORR 30%, DCR 93%, median PFS 6.3 months.
Leap Therapeutics sells IL-1ß antibody assets to AlmataBio for $500K cash plus up to $70M milestones
Entered into Asset Purchase Agreement with AlmataBio for IL-1ß antibodies FL-101 and FL-103.
Leap Therapeutics Q3 net loss $13.7M; DKN-01 colorectal study expands to Part B
Net loss $13.7M in Q3 2023 vs $15.1M in Q3 2022; cash and equivalents $80.7M.
Leap Therapeutics posts updated corporate presentation; no specifics in filing
Filed an 8-K on Sept 13, 2023, announcing an updated corporate presentation on www.leaptx.com.
Leap Therapeutics Q2 net loss $13.4M; DKN-01 CRC trial advances to Part B
Net loss $13.4M in Q2 2023 vs $17.0M in Q2 2022; R&D expenses fell to $11.1M.
Leap Therapeutics starts randomized Part B of DKN-01 Phase 2 CRC study after positive Part A
Initiated 130-patient randomized controlled Part B of DeFianCe study of DKN-01 in second-line advanced colorectal cancer.
Leap Therapeutics shareholders approve reverse split, equity plan; preferred converts to 24M shares
Directors Loscalzo, Mashiach, Mirabelli elected as Class III directors at annual meeting.
Leap Therapeutics effecting 10-for-1 reverse stock split to regain Nasdaq compliance
Reverse stock split ratio of 10-for-1, effective 5PM ET on June 20, 2023.
Median OS 19.5 months, median PFS 11.3 months in first-line GEA patients (n=25), exceeding current benchmarks.
Leap Therapeutics Q1 net loss $41.9M on $29.6M IPR&D charge; cash $102M
Net loss $41.9M ($10.4M Q1'22); includes $29.6M IPR&D charge from Flame acquisition.
Leap Therapeutics to present updated DKN-01/Gastric Cancer data at ASCO 2023
Will present long-term follow-up data from Part A of Phase 2 DisTinGuish study at ASCO June 2-6, 2023.
Part A enrolled 33 patients with advanced colorectal cancer; study is randomized, open-label, multicenter.
Leap Therapeutics amends CMO's severance; boosts benefits post-change-in-control
CMO Cynthia Sirard gets 100% base salary severance (12 monthly installments) on non-Cause termination or Good Reason resignation.
Leap Therapeutics removes requirement to file Flame Biosciences financials
Amendment to 8-K (filed Jan 23, 2023) deletes references to filing financial statements and pro forma info for Flame Biosciences acquisition.
Leap Therapeutics FY2022 net loss $54.6M; cash $65.5M plus $50M from Flame acquisition
Net loss $54.6M for 2022 (vs $40.6M in 2021); R&D expenses $45M (vs $32.2M).
BeiGene option for DKN-01 expired; Leap retains global rights, continues clinical collaboration
BeiGene's option to license DKN-01 in Asian territories expired; Leap retains global rights.
Leap Therapeutics acquires Flame Biosciences in merger, issuing ~19.8M shares and Series X Preferred
Acquired Flame Biosciences for approx 19.8M common shares and 136,833 Series X Convertible Preferred shares.
Acquired Flame for ~19.8M shares common + ~136.8k Series X preferred (convertible to 1,000 common each).
Leap Therapeutics reports Q3 2022 net loss of $15.1M, up from $11.1M YoY
Net loss $15.1M in Q3 2022 vs $11.1M in Q3 2021; R&D expenses $12.1M.
Cyndi Sirard, MD will be terminated without cause from her position as the Company’s Chief Medical Officer, effective on or about July 31, 2025
Augustine Lawlor will be terminated without cause from his position as the Company’s Chief Operating Officer, effective June 30, 2025
Patricia Martin and Christian Richard were appointed to the Board as directors.
Patricia Martin and Christian Richard were appointed to the Board as directors.
On September 1, 2022, the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) appointed Richard Schilsky, M.D. as a Class I director of the Board.
On August 11, 2022, Dr. Monica Bertagnolli, a director of the Company, informed the Company that she will be resigning as a director, effective August 12, 2022, as a result of her appointment as the 16th Director of the National Cancer Institute (NCI) by the Biden administration.
Max materiality 1.00 · Median 0.68 · Most common event other_material